Skip to main content
. Author manuscript; available in PMC: 2020 Jul 28.
Published in final edited form as: J Immunother. 2009 Feb-Mar;32(2):109–117. doi: 10.1097/CJI.0b013e31819302da

FIGURE 4.

FIGURE 4.

A, 3G8D increases interleukin (IL)-8 release from autologous renal cell carcinoma (RCC)/class II transactivation molecules (CIITA) depending on IL-17A. 3G8D and 8A1F were cocultured with autologous RCC/CIITA in the presence of anti–IL-17A monoclonal antibody or isotype control, or with HLA-DRB3*01 negative RCC/CIITA control for 24 hours. Concentration of IL-17A, IFN-γ, and IL-8 in the culture supernatants was measured by enzyme-linked immunosorbent assay (ELISA). B, Exogenous IL-17A increases IL-8 release from RCC cell lines. RCCs were treated with recombinant IL-17A for 24 hours, in the presence of anti–IL-17A monoclonal antibody or an isotype control antibody (iso). Concentration of IL-8 in the culture supernatants were measured by ELISA.